Overview of HAV, HBV and HCV surveillance systems and results in Lithuania IRMA Čaplinskienė Head of HIV/AIDS/STI and Hepatitis Surveillance, Centre for Communicable Diseases and AIDS; National ECDC contact for hepatitis /STI/ HIV; Member of the ECDC hepatitis B and C network; Member of the International AIDS Society Scientific Board Centre for Communicable Diseases and AIDS SAULIUS Čaplinskas Director, Centre for Communicable Diseases and AIDS; Professor Mykolas Romeris university, Vilnius VIRAL HEPATITIS PREVENTION BOARD MEETING RIGA,LATVIA, 19‐20 NOVEMBER 2015 PREVENTION AND CONTROL OF VIRAL HEPATITIS IN THE BALTIC STATES: LESSONS LEARN AND THE WAY FORWARD [email protected][email protected]
27
Embed
Overview of HAV, HBV, and HCV surveillance systems and ...€¦ · Overview of HAV, HBV and HCV surveillance systems and results in Lithuania IRMA ... Information System and data
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Overview of HAV, HBV and HCV surveillance systems and results in Lithuania
IRMA Čaplinskienė
Head of HIV/AIDS/STI and Hepatitis Surveillance, Centre for
Communicable Diseases and AIDS;National ECDC contact for hepatitis /STI/
HIV; Member of the ECDC hepatitis B and C network;
Member of the International AIDS Society Scientific Board
Centre for Communicable Diseases and AIDS
SAULIUS Čaplinskas
Director, Centre for Communicable Diseases and AIDS;
Professor Mykolas Romerisuniversity, Vilnius
VIRAL HEPATITIS PREVENTION BOARD MEETINGRIGA, LATVIA, 19‐20 NOVEMBER 2015
PREVENTION AND CONTROL OF VIRAL HEPATITIS IN THE BALTIC STATES: LESSONS LEARN AND THE WAY FORWARD
• LR MoH, 24/12/2002, Order No. 673 „On approval ofprocedure for compulsive epidemiological registration,obligatory content of information about objects forepidemiological registration and mandatory informationsubmission“
• LR MoH 10/02/2005, Order No. V‐109 „On adoption of formsfor communicable diseases statistical reporting andaccounting“
• LR MoH 14/01/2008, Order No. V‐19 „On approval ofCommunicable Diseases and Their Agents NationalInformation System and data security provisions ofCommunicable Diseases and Their Agents NationalInformation System “
Reporting on communicable diseases to the National Information System of
Communicable Diseases and their AgentsCase identification
(doctor)
PHcentres
Centre for Communicable Diseases and AIDS
Ministry of Health State Food and Veterinary Service
TESSy, WHO
Case data by primary diagnosis
Case based data
Case data
Communication by phone, mail, fax, email
Feedback
Source:
Communicable diseases (CD) cases and Incidence rate in Lithuania, 2007‐2014
721823
593341
757697
608226
745289
680240
851524
768157
22338,5
18552,2
23955,6
19637,4
24612,3
22767,5
28785,426195,8
0
5000
10000
15000
20000
25000
30000
35000
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
2007 2008 2009 2010 2011 2012 2013 2014
All CD
Rate per100 000population
Year
Source:
The structure of communicable diseases in Lithuania, 2014
Air borne diseases 95,76 %
Acute intestinal diseases 2,38%
TB 0,13%
Viral hepatitis 0,02%
Parasitoses1,49%
STI/HIV 0,13%
Other 0,08%
N= 762 588
Source:
1
2
3
4
5
6
Communicable Diseases in Lithuania in
2014
www.ulac.lt
13%
19%
25%
43%
Acute Viral Hepatitis in Lithuania
2014
2010
N=134
N=204
Nondiferentiated
7,8%
34,8%
20,1%
37,3%
HAVHBV
HCV
2010
N=204Source:
Incidence rate of acute viral hepatitis C and B(VHC and VHB) in Lithuania, 1990 – 2014
Number of vaccinations with HA vaccine in Lithuania, 2013 ‐ 2015
5151
3547
2371
5080
Source:
Children’s vaccination against VHB in Lithuania
• The newborns have been vaccinated against hepatitis B since 1998.
• Since 2002 vaccination against hepatitis B of the 12 years‐olds, who’s vaccination was finished in 2010, has been included into children’s preventative vaccination schedule because generation of the 12 years‐olds, who (as newborns) have been vaccinated since 1998, grew up.
Source:
Vaccination variationv (%), 2010 as compared to 2009
• HBV markers are found in 30% of global population• 1 mill. new infections occur annually in Europe• In EU countries VHB incidence is decreasing• HBsAg prevalence varies from 0,1% to 7% in general population in EU countries
HBsAg prevalence levels:<2% ‐ low, 2‐7% ‐moderate, >8% ‐ high
Source:
0.83.7
0.7
Source:European Centre for Disease Prevention and Control. Hepatitis B and C surveillance in Europe. 2012. Stockholm: ECDC; 2014.
Reported acute HBV per 100 000 population EU/EEA total 0.8
3.33.1
Source:European Centre for Disease Prevention and Control. Hepatitis B and C surveillance in Europe. 2012. Stockholm: ECDC; 2014.
Reported chronic HBV per 100 000 population
EU/EEA total 8.6
Prevalence of HCV infection
• HCV markers are found in 3% of global population• 2 mill. new HCV infections worldwide each year• About 30 000 new hepatitis C cases are reported in EU and EEA countries each year.
• In EU countries VHC incidence is decreasing• Anti‐HCV prevalence varies from 0.4% to 3.5% in general population in EU countries
Anti‐HCV prevalence levels:≤1% ‐ Low>1‐≤2% ‐Medium>2% ‐ High
Source:
Reported overal VHC per
100 000 population
EU/EEA total 7.8
Source:European Centre for Disease Prevention and Control. Hepatitis B and C surveillance in Europe. 2012. Stockholm: ECDC; 2014.
Source: Health Consumer Powerhouse. Euro Hepatitis Index 2012 Reporthttp://www.healthpowerhouse.com/files/euro-hepatitis-index-2012/Report-Hepl-HCP-121104-2-w-Cover.pdf
Total score 1000
Source: Health Consumer Powerhouse. Euro Hepatitis Index 2012 Reporthttp://www.healthpowerhouse.com/files/euro-hepatitis-index-2012/Report-Hepl-HCP-121104-2-w-Cover.pdf